N@N

Sunesis to Host Conference Call on Tuesday, December 8th to Discuss New Phase 2 Voreloxin Data Presented at ASH

^{Published on 2009-12-01 04:40:50 - Market Wire}
 

SOUTH SAN FRANCISCO, CA--(Marketwire - December 1, 2009) - Sunesis Pharmaceuticals, Inc. (NASDAQ: [ SNSS ]) today announced that the company will host a conference call on Tuesday, December 8, 2009 at 2:00 PM EST to discuss the new clinical data from its Phase 2 voreloxin program presented at the 51st Annual American Society of Hematology (ASH) Meeting in New Orleans. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team to review updated data from both its Phase 2 combination study of voreloxin and cytarabine in relapsed or refractory AML patients and the REVEAL-1 study, a Phase 2 dose regimen optimization study of single agent voreloxin in newly diagnosed elderly AML patients who are unlikely to benefit from standard induction chemotherapy.

The call can be accessed by dialing 888-726-2443 (U.S. and Canada) or 913-312-1516 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at [ www.sunesis.com ]. The webcast will be recorded and available for replay on the company's website until December 22, 2009.

ASH Presentations

Following are the details of the voreloxin presentations at ASH:

• Poster Presentation: Phase 2 Dose Regimen Optimization Study of Voreloxin as Single Agent Therapy for Frontline, Elderly AML. Ernest N. Morial Convention Center, Hall E. Abstract # 1037. Poster Board I-59. Saturday, December 5, 9:00AM - 7:30PM CST viewing, 5:30PM - 7:30PM CST presentation.
• Oral Presentation: Phase 1b/2 PK/PD Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory AML Patients. Ernest N. Morial Convention Center, Rooms 343-345. Abstract #635. Monday, December 7, 4:30PM - 6:00PM CST session time, presentation 5:30PM CST.

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit [ http://www.sunesis.com ].

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.